FDA Grants Accelerated Approval for OTOF Gene Therapy A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial. By Kathryn Wighton April 23, 2026 3 min MDSpire News Share Summary Takeaways Listen Insight Report Quiz Poll